Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $16.4 million.

  • Cytek Biosciences' Other Accumulated Expenses rose 8636.26% to $16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year increase of 8636.26%. This contributed to the annual value of $13.5 million for FY2024, which is 7074.53% up from last year.
  • As of Q3 2025, Cytek Biosciences' Other Accumulated Expenses stood at $16.4 million, which was up 8636.26% from $14.7 million recorded in Q2 2025.
  • Cytek Biosciences' Other Accumulated Expenses' 5-year high stood at $16.4 million during Q3 2025, with a 5-year trough of $1.4 million in Q2 2021.
  • Over the past 5 years, Cytek Biosciences' median Other Accumulated Expenses value was $8.1 million (recorded in 2022), while the average stood at $8.5 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 31672.83% in 2022, then plummeted by 2424.27% in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' Other Accumulated Expenses stood at $6.4 million in 2021, then increased by 25.31% to $8.0 million in 2022, then fell by 0.72% to $7.9 million in 2023, then skyrocketed by 70.75% to $13.5 million in 2024, then increased by 21.73% to $16.4 million in 2025.
  • Its Other Accumulated Expenses stands at $16.4 million for Q3 2025, versus $14.7 million for Q2 2025 and $12.8 million for Q1 2025.